Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.

Lu, Mei; Xing, Haonan; Zheng, Aiping; Huang, Yuanyu; Liang, Xing-Jie

Lu, Mei; Xing, Haonan; Zheng, Aiping; Huang, Yuanyu; Liang, Xing-Jie.

Afiliação

Lu M; Advanced Research Institute of Multidisciplinary Science, School of Life Science, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, No. 5, South Street, Zhonggu
Xing H; Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing 100190, China.
Zheng A; Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing 100190, China.
Huang Y; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, No. 27, Taiping Road, Beijing 100850, China.
Liang XJ; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, No. 27, Taiping Road, Beijing 100850, China.

Acc Chem Res ; 56(3): 224-236, 2023 02 07.

Article em En | MEDLINE | ID: mdl-36624086

Assuntos

COVID-19; Nanoestruturas; Humanos; Proteínas; RNA Mensageiro; Desenvolvimento de Medicamentos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Nanoestruturas / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Acc Chem Res Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google